| Domain | Established finding | Quantitative evidence/examples | Evidence type and year | Certainty/gap |
|---|---|---|---|---|
| Disease definition / embryology | Vein of Galen aneurysmal malformation (VGAM/VOGM) is a congenital high-flow brain arteriovenous shunt between primitive choroidal or subependymal arteries and the median prosencephalic vein of Markowski, without an intervening capillary bed; it arises during fetal cerebrovascular development and is anatomically distinct from pial AV fistulas that merely drain into the vein of Galen. | Development reported during fetal weeks 6-11; true VGAM defined by drainage into the embryonic median prosencephalic vein with normal brain venous drainage rerouted through alternative pathways. (pqac-00000000, pqac-00000005, pqac-00000002) | Human clinical/review evidence, 2022-2023 | High certainty for definition and embryologic concept; exact embryologic timing varies slightly across sources. |
| Epidemiology | VGAM is rare but is among the most important vascular malformations in fetuses and infants. | Reported incidence ranges in available sources from ~1:25,000 to ~1:50,000; accounts for ~30% of pediatric vascular malformations; male predominance reported around 3:1 in one source. (pqac-00000000, pqac-00000003) | Human clinical/review evidence, 2018-2022 | Moderate certainty; incidence and sex-ratio estimates vary by source and older literature. |
| Major phenotypes | The major morbidity drivers are neonatal high-output cardiac failure, hydrocephalus/venous congestion, intracranial hemorrhage risk, seizures, developmental delay, and neurologic deficits. Presentation varies by age and shunt anatomy. | In a pediatric cohort of 115 children with cerebral high-flow shunts, good outcome occurred in 62% and poor outcome in 38%; median follow-up 27 months among survivors. Antenatal cardiac failure has been associated with very high mortality in older literature summarized by recent sources. (pqac-00000002, pqac-00000000, pqac-00000001, pqac-00000005) | Human cohort/review evidence, 2022-2023 | High certainty for phenotype spectrum; precise phenotype frequencies by subtype are incompletely standardized in currently available context. |
| Genetics: overall architecture | VGAM is often sporadic, but a substantial minority of patients carry rare damaging germline variants in vascular-development genes; both de novo and inherited variants contribute. | 310 proband-family exomes analyzed in the largest available study; de novo variants estimated to contribute to ~12% of cases; 115-child cohort found pathogenic/likely relevant variants in 39% overall. (pqac-00000008, pqac-00000009, pqac-00000004) | Human genomic cohort evidence, 2022-2023 | High certainty that genetics contributes in a subset; overall attributable fraction remains incomplete. |
| Genetics: RASA1 | RASA1 is the strongest currently supported VGAM gene, with loss-of-function de novo and transmitted germline variants implicating dysregulated Ras suppression. | Genome-wide significant burden of de novo loss-of-function variants: 2042.5-fold enrichment, p=4.79×10^-7; case-control enrichment versus gnomAD Fisher p=2.20×10^-8, OR=67.50; example variants include p.Arg427*, p.Val527Mfs*16, p.Arg709*, p.Tyr695*/p.Tyr872* and frameshift alleles. (pqac-00000008, pqac-00000010, pqac-00000011) | Human exome study and prior cohort, 2023 | High certainty for association; penetrance is incomplete and phenotype can include other vascular anomalies. |
| Genetics: EPHB4 | EPHB4 is strongly associated with true VGAM and appears especially informative for distinguishing genuine VGAM from other cerebral AV shunts. Most disease alleles impair receptor function rather than simply destabilizing protein. | Rare damaging transmitted variants enriched 17.5-fold, p=1.22×10^-5; in one 115-child cohort EPHB4 variants represented 8% of identified variants and were observed only in genuine VGAM; example kinase-domain missense variant p.Phe867Leu. (pqac-00000008, pqac-00000007, pqac-00000004, pqac-00000013) | Human genomic cohort and functional studies, 2018-2023 | High certainty for association with genuine VGAM; exact penetrance and full allelic spectrum remain incompletely defined. |
| Genetics: ACVRL1, NOTCH1, ITGB1, PTPN11 | Additional genes affecting vascular development/signaling are implicated in smaller numbers of patients, broadening VGAM biology beyond the core RASA1-EPHB4 axis. | ACVRL1 variants identified including p.Cys344Tyr and p.Arg484Gln; PTPN11 example p.Tyr63Cys; NOTCH1 and ITGB1 damaging variants also reported. ACVRL1 variants occurred in a multigenerational pedigree. (pqac-00000007, pqac-00000008, pqac-00000009, pqac-00000011) | Human exome cohort evidence, 2023 | Moderate certainty; gene-specific case counts are small and some genes remain candidate-level compared with RASA1/EPHB4. |
| Inheritance / penetrance | The best-supported inherited forms show autosomal dominant transmission with incomplete penetrance and variable expressivity; some carriers have capillary malformations or other vascular phenotypes rather than VGAM. A two-hit mechanism is hypothesized for some families. | Inherited RASA1/EPHB4 variants showed nonpenetrance or alternate phenotypes in family studies; prior cohort estimated inherited damaging ephrin-signaling variants accounted collectively for ~30% of cases in a 55-proband exome series. (pqac-00000013, pqac-00000012, pqac-00000006) | Human family-based genomic evidence, 2019-2023 | Moderate-to-high certainty for incomplete penetrance/variable expressivity; direct proof of second-hit somatic events in VGAM remains limited in current context. |
| Endothelial Ras/MAPK mechanism | The central mechanistic model is dysregulation of an endothelial Ras/ERK/MAPK signaling network during cerebrovascular development, impairing arterial-capillary-venous hierarchy formation and vascular remodeling. | Developing endothelial cells emerged as the likely spatiotemporal disease locus from analysis of 336,326 cerebrovascular single-cell transcriptomes; VOGM genes showed endothelial enrichment (p=6.43×10^-6) and vascular-development pathway enrichment including 11.4-fold enrichment for positive regulation of vascular development, p=7.95×10^-8. (pqac-00000008, pqac-00000007, pqac-00000009, pqac-00000006) | Human genomics + single-cell transcriptomics, 2023 | High certainty for endothelial developmental locus and Ras-network involvement; downstream hemodynamic injury pathways are less finely quantified. |
| Diagnostics | Diagnosis relies primarily on prenatal ultrasound and fetal MRI, then postnatal neurovascular imaging and hemodynamic assessment to define anatomy, organ dysfunction, and treatment timing. | Prenatal detection is commonly in late 2nd or 3rd trimester in summarized sources; fetal trials use MRI markers such as straight/falcine sinus width ≥7 mm to identify high-risk fetuses. (pqac-00000000, pqac-00000014, pqac-00000015) | Human clinical and trial-protocol evidence, 2022-2026 | Moderate certainty; detailed modern sensitivity/specificity data and formal scoring-system thresholds were not available in current context. |
| Standard treatment: endovascular embolization | Staged endovascular embolization is the current treatment standard for symptomatic or high-risk VGAM, typically performed after stabilization and tailored to angioarchitecture. | Multiple current sources describe endovascular embolization as prognosis-improving standard care; untreated disease has been described as nearly uniformly fatal in severe infantile presentations. (pqac-00000003, pqac-00000004, pqac-00000005) | Human clinical/review evidence, 2018-2023 | High certainty for standard-of-care status; precise pooled success/complication rates were not available in current retrievable context. |
| Experimental fetal embolization trials | Fetal embolization is an emerging strategy for fetuses predicted to decompensate immediately after birth, aiming to reduce urgent neonatal intervention and early mortality. | NCT04434729: prospective single-arm fetal embolization study, enrollment 7, active/not recruiting; NCT07483255: Phase II recruiting trial, planned enrollment 20. Both use maternal transuterine, fetal transcranial torcular puncture with median prosencephalic vein coil embolization; inclusion requires falcine/straight sinus width ≥7 mm and preserved brain parenchyma. (pqac-00000015, pqac-00000014) | Interventional trial protocol evidence, 2022-2026 | Moderate certainty for feasibility research; efficacy and long-term safety remain investigational. |
| Prognosis | Prognosis is driven by timing/severity of cardiac failure, brain injury, hydrocephalus/venous congestion, and feasibility of staged embolization; modern outcomes are markedly better than historical natural history. | 115-child cohort: 62% good vs 38% poor outcome overall; severe antenatal cardiac failure has been associated with very high mortality in summarized literature. (pqac-00000002, pqac-00000000) | Human cohort/review evidence, 2022-2023 | Moderate certainty; contemporary multicenter long-term neurodevelopmental rates were not fully available in current context. |
| Prevention | There is no established primary prevention for sporadic VGAM. Secondary prevention focuses on prenatal detection and early referral; in familial forms, genetic counseling and targeted testing are relevant. | Familial syndromic associations include RASA1/EPHB4-related capillary malformation-AVM and HHT genes such as ACVRL1/ENG; pregnancy surveillance in known carriers has been advocated in review/case literature. (pqac-00000003, pqac-00000000, pqac-00000009) | Human genetic and clinical evidence, 2018-2023 | Moderate certainty for counseling/surveillance; no proven environmental or pharmacologic preventive factors identified. |
| Model organisms | Functional animal models support causality and mechanism, especially for endothelial signaling genes. | Mouse model expressing EPHB4 p.Phe867Leu showed disrupted developmental angiogenesis and impaired arterial-capillary-venous hierarchy, particularly with a second-hit allele; zebrafish Acvrl1a/b depletion produced VOGM-like venous dilation rescued by wild-type but not mutant ACVRL1. (pqac-00000008, pqac-00000007, pqac-00000011, pqac-00000012) | Mouse and zebrafish functional studies, 2019-2023 | High certainty that these models recapitulate key vascular-development features; no well-established natural nonhuman disease species identified in current context. |


*Table: This table summarizes the strongest currently available evidence for vein of Galen aneurysmal malformation across definition, epidemiology, clinical features, genetics, mechanisms, diagnosis, treatment, prognosis, prevention, and models. It is designed as a concise knowledge-base matrix that distinguishes established findings from current evidence gaps.*